Psychotropic drug-induced change of weight: a review

Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial

“…It is well established that patients treated with OLZ or other atypical antipsychotic drugs are at increased risk of developing lipid and glucose disturbances (Newcomer et al 2002(Newcomer et al , 2009Nasrallah and Newcomer 2004;Henderson et al 2005;Drieling et al 2007;Newcomer 2007;Kantrowitz and Citrome 2008;Correll et al 2009). As such we were very interested in monitoring temporal changes in lipid and glucose levels.…”

“…As such, our results suggest that a complex weight management program has positive long-term effects in weight-management interventions are effective at attenuating antipsychotic-induced weight, there is little evidence for their long-term effectiveness. Patients with schizophrenia who are treated with antipsychotic drugs are known to be at high risk of developing type 2 diabetes, and treatment with OLZ is associated not only with substantial body weight gain but also with the development of dyslipidemia and diabetes (Drieling et al 2007). Although weight gain is well known as a promoter of manifest type 2 diabetes (Smith and Porter 2009), recent studies suggest that at least some patients taking second-generation antipsychotics can experience new-onset diabetes without any changes in body weight (Fenton and Chavez 2006).…”

“…However, amongst second-generation antipsychotic drugs, clozapine and OLZ in particular were found to be associated with a high risk of weight gain as well as with an increased risk of developing type 2 diabetes and dyslipidemia (Nasrallah and Newcomer 2004;Ascher-Svanum et al 2005;Haddad 2005;Drieling et al 2007;Kinon et al 2005;Newcomer 2007;McElroy 2009). A recent study compared changes in glucose metabolism in patients with schizophrenia receiving OLZ, quetiapine, or risperidone, and found a greater disturbance of glucose tolerance during a 6-month treatment in patients treated with OLZ and quetiapine (Newcomer et al 2009).…”

MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?

“…Therefore, patients on co-medication known for its clear influence on weight gain (tricyclic antidepressant, mirtazapine, lithium, valproic acid and paroxetine) were excluded (Drieling et al, 2007). One subject had to be excluded from BMI analyses because height measurement was missing.…”

Pharmakotherapie der Depression bei Menschen mit Diabetes

“…Bei beiden dual wirksamen Substanzen werden gastrointestinale Nebenwirkungen und sexuelle Dysfunktion in einem vergleichbaren Ausmaß gefunden wie bei der Behandlung mit SSRI. Einzelne, wenngleich nicht alle Studien fanden darüber hinaus eine Gewichtszunahme unter Venlafaxin [16].…”